Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS

 
• By Jessica Merrill

A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).

Two hands signalling thumbs up and thumbs down. The smooth hand on the left is making a thumbs up gesture while the hairy hand on the right is making a thumbs down gesture.
Ovid/Takeda reported mixed Phase II data in rare epilepsies • Source: Shutterstock

More from Neurological

More from Therapy Areas